We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Radius Health (RDUS) Posts Wider-than-Expected Q2 Loss
Read MoreHide Full Article
Radius Health, Inc. (RDUS - Free Report) is a Waltham, Massachusetts-based development-stage biopharmaceutical company with a focus on the development of new therapeutics for the treatment of osteoporosis and other serious endocrine-mediated diseases.
With no approved products in its portfolio, Radius Health has not generated revenues yet. In this scenario, investor focus remains on updates on pipeline progress.
The company’s lead candidate, abaloparatide subcutaneous (abaloparatide-SC), is being developed for reducing the risk of fractures in postmenopausal osteoporosis. The candidate is currently under review in both the U.S. and the EU. It expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its application in late 2016 or in 2017.
A potential approval would allow Radius Health to record its first commercial sales. The company is looking for a partner to commercialize abaloparatide.
Radius Health has a disappointing track record so far. The company has missed estimates in all of the four trailing quarters with a negative average surprise of 15.62%.
Currently, Radius Health has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Radius Health posted wider-than-expected loss in the second quarter of 2016. While our consensus called for a loss of 98 cents per share, the company reported a loss of $1.01.
Revenue: With no approved product in its portfolio, Radius Health has not generated any revenues in the reported quarter.
Key Stats: Radius Health is currently seeking a commercialization partner for abaloparatide-SC prior to launch. The company’s New Drug Application (NDA) for abaloparatide-SC is currently under review in the U.S. with an action date of Mar 30, 2017. Radius Health is also developing abaloparatide-transdermal, (abaloparatide-TD) as a short wear-time transdermal patch.
Check back for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Radius Health (RDUS) Posts Wider-than-Expected Q2 Loss
Radius Health, Inc. (RDUS - Free Report) is a Waltham, Massachusetts-based development-stage biopharmaceutical company with a focus on the development of new therapeutics for the treatment of osteoporosis and other serious endocrine-mediated diseases.
With no approved products in its portfolio, Radius Health has not generated revenues yet. In this scenario, investor focus remains on updates on pipeline progress.
The company’s lead candidate, abaloparatide subcutaneous (abaloparatide-SC), is being developed for reducing the risk of fractures in postmenopausal osteoporosis. The candidate is currently under review in both the U.S. and the EU. It expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its application in late 2016 or in 2017.
A potential approval would allow Radius Health to record its first commercial sales. The company is looking for a partner to commercialize abaloparatide.
Radius Health has a disappointing track record so far. The company has missed estimates in all of the four trailing quarters with a negative average surprise of 15.62%.
Currently, Radius Health has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Radius Health posted wider-than-expected loss in the second quarter of 2016. While our consensus called for a loss of 98 cents per share, the company reported a loss of $1.01.
Revenue: With no approved product in its portfolio, Radius Health has not generated any revenues in the reported quarter.
Key Stats: Radius Health is currently seeking a commercialization partner for abaloparatide-SC prior to launch. The company’s New Drug Application (NDA) for abaloparatide-SC is currently under review in the U.S. with an action date of Mar 30, 2017. Radius Health is also developing abaloparatide-transdermal, (abaloparatide-TD) as a short wear-time transdermal patch.
RADIUS HEALTH Price
RADIUS HEALTH Price | RADIUS HEALTH Quote
Check back for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>